Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complicationsJean Klastersky, Marianne Paesmans, Aspasia Georgala, et al.
BMC Cancer|June 3, 2021
Prophylactic gastrostomy in locally advanced head and neck cancer: results of a national survey among radiation oncologistsTatiana Dragan, Fréderic Duprez, André Van Gossum, et al.
Current Medical Research and Opinion|May 24, 2007
A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignanciesAhmad Awada, Steven Zhang, Thierry Gil, et al.
The Oncologist|September 14, 2020
Meta-Analysis on Induction Chemotherapy in Locally Advanced Nasopharyngeal CarcinomaMaïmouna Mané, Sofian Benkhaled, Tatiana Dragan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 20, 2012
EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinomaYassine Lalami, Pol M Specenier, Ahmad Awada, et al.
BMC Cancer|November 25, 2010
The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphomaLaetitia Gerlier, Mark Lamotte, Ahmad Awada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2023
Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111-24111)Simon P Beyaert, Axelle E Loriot, Nicolas D Huyghe, et al.
Frontiers in Endocrinology|July 17, 2024
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, et al.
Trials|December 20, 2022
Patient-reported outcomes in terms of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced oropharyngeal cancer patients treated with definitive chemo-radiotherapy: Swall PEG studyTatiana Dragan, André Van Gossum, Frederic Duprez, et al.
Pageof 2